Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMAP long-term open-label extension of mirikizumab for moderately to severely active ulcerative colitis
MOH_2020-03-26_008807Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mirikizumab in autoimmune colitis, sponsored by Eli Lilly and Company. Started Mar 2020; status: active, not recruiting.
02
Drugs
mirikizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2020-03-26_008807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-03-26_008807.